- Home
- NRO vs HURA Comparison
NRO vs HURA Comparison
Compare NRO & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | NRO | HURA |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.3M | 160.5M |
| IPO Year | 2003 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NRO | HURA |
|---|---|---|
| Price | $2.55 | $2.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.04 |
| AVG Volume (30 Days) | 222.3K | ★ 250.0K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.48 | $0.41 |
| 52 Week High | $3.23 | $3.43 |
Technical Indicators
Market Signals| Indicator | NRO | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.70 | 59.70 |
| Support Level | $2.49 | $2.06 |
| Resistance Level | $2.61 | $2.22 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 46.19 | 92.86 |
Price Performance
Historical ComparisonAbout NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.